Risdiplam – one step away from approval
The US Food and Drug Administration (known as the FDA) has accepted regulatory documentation for a drug called “Risdiplam”, as the most innovative therapeutic treatment for SMA types 1,2 and 3, and has been prioritized for evaluation of the impact that manifests on patients. The documentation is based on the Read more…
